FLICKR, DOMINIC ALVES”The era of the oncolytic virus is probably here,” Stephen Russell, a cancer researcher and haematologist at the Mayo Clinic in Rochester, Minnesota, told Nature.
Yesterday, the US Food and Drug Administration greenlighted Amgen’s T-VEC, a genetically engineered herpesvirus called talimogene laherparepvec, for the treatment of melanoma lesions in the skin and lymph nodes, making it the first oncolytic virus to receive market approval.
Dozens of other oncolytic viruses are currently being tested in clinical trials. The therapy is based on a simple principle: many viruses will preferentially infect cancer cells and spur an immune reaction that will wipe out the diseased cells. While this phenomenon has long been recognized, it took decades of research to develop an effective and safe therapy. T-VEC has been engineered to reduce its ability to cause herpes and to add an immune-stimulating gene to make the therapy a more-potent cancer killer.
“Advanced melanoma remains a complex disease to treat, requiring the use of several modalities over the course of a patient’s therapeutic journey,” Howard Kaufman, associate director for Clinical Science at the Rutgers Cancer Institute of New Jersey and a PI for the latest T-VEC trial, said in a statement.